Business Context and Reporting Period
Company: iBioPharma, Inc. (formerly InB:Biotechnologies, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2008
Business Overview: A biotechnology company focused on a proprietary plant-based expression platform for producing vaccines, antibodies, and therapeutic proteins. The company also produces nutritional supplements via hydroponic growth. In August 2008, the company completed a spin-off from its former parent, Integrated BioPharma, Inc., becoming an independent public entity traded on the OTC Bulletin Board.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2008 | Three Months Ended Sep 30, 2007 |
|---|---|---|
| Net Sales | $333,400 | $239,600 |
| Cost of Sales | $135,600 | $118,000 |
| Gross Margin | 59.3% | 50.8% |
| Research & Development | $250,000 | $0 |
| Selling & Admin Expenses | $497,400 | $498,000 |
| Net Income/Loss | Not explicitly stated (Operating Loss approx. $549,600) | Not explicitly stated |
| Cash Flow from Operations | ($778,100) used | ($439,200) used |
| Cash Flow from Financing | $4.2 million provided | Not explicitly stated |
| Working Capital | $2.3 million | N/A |
| Cash Balance | Approx. $2.9 million (uninsured portion noted) | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 39% to $333,400, driven by a new subcontract agreement with FhCMB (40.9% of sales) related to a DARPA grant, diversifying away from reliance on the Mannatech supply agreement.
- R&D Expenses: R&D costs increased to $250,000 from $0, primarily due to milestone payments to FhCMB for flu vaccine research.
- Corporate Support: Selling and administrative expenses remained flat overall, but corporate support charges from the former parent decreased by 78% ($84,200) following the spin-off. This was offset by a $125,200 increase in salaries and benefits due to new hires.
- Liquidity: Working capital improved from a negative $1.8 million (June 30, 2008) to a positive $2.3 million (September 30, 2008) following a $5.0 million private placement.
Guidance, Outlook, and Risks
- Capital Raise: In August 2008, the company closed a $5.0 million private placement, netting approximately $4.6 million. Management expects these funds to cover anticipated costs through the first quarter of calendar year 2010.
- Operational Outlook: Clinical trials for the plant-based flu vaccine are expected to begin in the second quarter of 2009. A prototype production facility is scheduled for validation in Q1 2009.
- Future Financing: The company no longer has financial support from Integrated BioPharma. Failure to secure additional financing by early 2010 could force the company to abandon commercialization efforts or cease operations.
- Risks:
- Customer Concentration: Three customers accounted for approximately 100% of revenue in Q3 2008 (40.9%, 36.6%, and 22.1%).
- Cost Structure: Cost of goods sold is expected to increase from 50% to 90% of sales due to new supply agreements with related parties post-spin-off.
- Commitments: The company has a remaining commitment of $300,000 to FhCMB for intellectual property and potential future R&D commitments of $1.2 million to $10.0 million depending on milestones.
Investor Verification Checklist
- Cash Runway: Verify if the $4.6 million net proceeds are sufficient to reach the Q1 2010 milestone given the burn rate of ~$778k per quarter in operating cash flow.
- Customer Dependency: Assess the risk of losing the FhCMB DARPA contract, which now represents the largest single revenue source (40.9%).
- Cost of Goods Sold: Confirm the impact of the projected increase in COGS to 90% of sales on future gross margins.
- Related Party Transactions: Review the Transitional Services Agreement and supply agreements with Integrated BioPharma subsidiaries for terms and pricing fairness.
- Intellectual Property Commitments: Monitor the $300,000 remaining payment to FhCMB and the potential $10 million future R&D commitment.